source
- Merck briefly lists, then removes, phase 2 trial of PD-1xVEGF bispecific with TROP2 ADCMerck & Co. posted a clinical trial listing for a phase‑2 study combining its PD‑1xVEGF bispecific antibody (MK‑2010) with the TROP2‑directed antibody‑drug conjugate sac‑TMT. The listing, shown as…
- Nokia reports senior executive Kristen Pressner purchases 66,324 shares at €7.84 eachNokia Oyj filed a market abuse regulation disclosure on July 29, 2026 indicating that senior executive Kristen Pressner bought shares of the company. The transaction involved 66,324 ordinary share…